13,14-Dihydro-15-keto-20-ethyl prostaglandin f2alpha

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 13,14-Dihydro-15-keto-20-ethyl prostaglandin f2alpha
• 英文别名: 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoic acid
• 化学式: C₂₂H₃₈O₅
• 分子量: 382.5
• InChiKey: TVHAZVBUYQMHBC-MXEMCNAFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF ISOMER FREE PROSTAGLANDINS
  申请人：CHIROGATE INTERNATIONAL INC.

  公开号：US20150051410A1

  公开（公告）日：2015-02-19

  Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer: wherein R 2 , R 3 and R 4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.

  提供了一种用于制备基本上不含5,6-顺式异构体的化合物I-2的新工艺：其中R2、R3和R4如规范中定义。还提供了用于制备无异构体前列腺素及其衍生物的新中间体。
• BIFUNCTIONAL RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE
  申请人：INSPIRE PHARMACEUTICALS, INC.

  公开号：US20130131106A1

  公开（公告）日：2013-05-23

  This invention relates to synthetic bifunctional compounds comprising a first rho-associated kinase (ROCK) inhibiting compound and a second pharmaceutically active compound with complementary activity; the first and the second compounds are covalently linked by a biologically labile bond. This invention also relates to methods of making such compounds. The invention also relates to methods of using such bifunctional compounds in the prevention or treatment of diseases or conditions that are affected or can be assisted by altering the integrity or rearrangement of the cytoskeleton. Particularly, this invention relates to methods of treating ophthalmic diseases such as disorders in which intraocular pressure is elevated, for example primary open-angle glaucoma, using the bifunctional compounds.

  本发明涉及合成的双功能化合物，包括第一种抑制rho相关激酶(ROCK)的化合物和具有互补活性的第二种药物活性化合物；第一种和第二种化合物由生物可降解的化学键共价连接。本发明还涉及制备这种化合物的方法。本发明还涉及使用这种双功能化合物预防或治疗受到细胞骨架完整性或重组影响的疾病或病况的方法。特别地，本发明涉及使用这种双功能化合物治疗眼科疾病，例如原发性开角型青光眼等眼内压升高的疾病。
• Use of 15-keto-prostanoic acid derivatives in the manufacture of a medicament for improvement of excretion of potassium ion
  申请人：Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo

  公开号：EP0410652A2

  公开（公告）日：1991-01-30

  A use of a prostanoic acid derivative for the manufacture of a medicament for inducing decrease in potassium ion concentration in the blood.

  一种利用前列酸衍生物制造可降低血液中钾离子浓度的药物。
• Use of prostanoic acid derivaties for the manufacture of a medicament for improvement of excretion of nonprotein nitrogen into the intestine
  申请人：Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo

  公开号：EP0415564A2

  公开（公告）日：1991-03-06

  A use of a prostanoic acid derivative for the manufacture of a medicament for improvement of excretion of nonprotein nitrogen into the intestine.

  一种利用前列酸衍生物制造改善非蛋白氮排入肠道的药物。
• Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
  申请人：R-TECH UENO, LTD.

  公开号：EP0424156A2

  公开（公告）日：1991-04-24

  A use of a 15-ketoprostaglandin compound for the manufacture of a medicament for treatment of a hepatobiliary disease.

  一种 15-酮前列腺素化合物用于制造治疗肝胆疾病药物的用途。